Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Nathan L. Avaritt"'
Autor:
Samrat Roy Choudhury, Billie Heflin, Erin Taylor, Brian Koss, Nathan L. Avaritt, Alan J. Tackett
Publikováno v:
Cells, Vol 12, Iss 5, p 730 (2023)
Overexpression of S100B is routinely used for disease-staging and for determining prognostic outcomes in patients with malignant melanoma. Intracellular interactions between S100B and wild-type (WT)-p53 have been demonstrated to limit the availabilit
Externí odkaz:
https://doaj.org/article/e7345b6aabc44c319409ca09f099225a
Autor:
Ishan Barman, Narasimhan Rajaram, Alan J. Tackett, Stephanie D. Byrum, Charles M. Quick, Allen J. Gies, Nathan L. Avaritt, David E. Lee, Jesse D. Ivers, Paola Monterroso Diaz, Piyush Raj, Joel Rodriguez Troncoso, Santosh Kumar Paidi
Cancer immunotherapy provides durable clinical benefit in only a small fraction of patients, and identifying these patients is difficult due to a lack of reliable biomarkers for prediction and evaluation of treatment response. Here, we demonstrate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624098e667551aa0c755db084de732d1
https://doi.org/10.1158/0008-5472.c.6513670
https://doi.org/10.1158/0008-5472.c.6513670
Autor:
Ishan Barman, Narasimhan Rajaram, Alan J. Tackett, Stephanie D. Byrum, Charles M. Quick, Allen J. Gies, Nathan L. Avaritt, David E. Lee, Jesse D. Ivers, Paola Monterroso Diaz, Piyush Raj, Joel Rodriguez Troncoso, Santosh Kumar Paidi
Supplementary figures S1 and S2 and supplementary tables ST1 and ST2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6ded52a84d28c4bcdcc53106ee3456
https://doi.org/10.1158/0008-5472.22430638
https://doi.org/10.1158/0008-5472.22430638
Autor:
Stephanie D. Byrum, Nathan L. Avaritt
Publikováno v:
Journal of Visualized Experiments.
Autor:
Kanishka Manna, Prashanthi Dharanipragada, Duah H. Alkam, Nathan L. Avaritt, Charity L. Washam, Michael S. Robeson, Tung-Chin Chiang, Ricky D. Edmondson, Samuel Mackintosh, Zhentao Yang, Yan Wang, Shirley Lomeli, Gatien Moriceau, Stephanie D. Byrum, Roger Lo, Alan J. Tackett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5e0aaaa7c534f3affd751e80e55025d
https://doi.org/10.2139/ssrn.4366097
https://doi.org/10.2139/ssrn.4366097
Autor:
Kanishka Manna, Prashanthi Dharanipragada, Duah Alkam, Nathan L. Avaritt, Charity L. Washam, Tung-chin Chiang, Michael S Robeson, Ricky D. Edmondson, Samuel G. Mackintosh, Zhentao Yang, Yan Wang, Shirley H. Lomeli, Gatien Moriceau, Roger S. Lo, Alan J. Tackett, Stephanie D. Byrum
Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activatingBRAFV600mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b31ecbe4a7f506bf06d484cfc388b48
https://doi.org/10.17504/protocols.io.b68erhte
https://doi.org/10.17504/protocols.io.b68erhte
Autor:
Kanishka Manna, Prashanthi Dharanipragada, Duah Alkam, Nathan L. Avaritt, Charity L. Washam, Michael S. Robeson, Ricky D. Edmondson, Samuel G. Mackintosh, Zhentao Yang, Yan Wang, Shirley H. Lomeli, Gatien Moriceau, Stephanie D. Byrum, Roger S. Lo, Alan J. Tackett
Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activating BRAFV600 muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0c901c8d9ebf37fbe61741e5a30391d
https://doi.org/10.1101/2022.02.15.480454
https://doi.org/10.1101/2022.02.15.480454
Autor:
Narasimhan Rajaram, Piyush Raj, Charles M. Quick, Jesse D. Ivers, Nathan L. Avaritt, Ishan Barman, Alan J. Tackett, David E. Lee, Paola Monterroso Diaz, Allen J. Gies, Santosh Kumar Paidi, Joel Rodriguez Troncoso, Stephanie D. Byrum
Publikováno v:
Cancer Res
Cancer immunotherapy provides durable clinical benefit in only a small fraction of patients, and identifying these patients is difficult due to a lack of reliable biomarkers for prediction and evaluation of treatment response. Here, we demonstrate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6fe0b77404f9c0e8c484337a02c972c
https://europepmc.org/articles/PMC8841097/
https://europepmc.org/articles/PMC8841097/
Control of the Anterior Pituitary Cell Lineage Regulator POU1F1 by the Stem Cell Determinant Musashi
Autor:
Linda L. Hardy, Nathan L. Avaritt, Christopher J. Lengner, Melanie C. MacNicol, Christian L Thomas, Michael G. Kharas, Angus M. MacNicol, Gwen V. Childs, Jordan T. Bird, Melody Allensworth-James, Stephanie D. Byrum, Angela K. Odle, Jewel Banik, Alex N. LaGasse, Ana Rita Silva Moreira
Publikováno v:
Endocrinology
The adipokine leptin regulates energy homeostasis through ubiquitously expressed leptin receptors. Leptin has a number of major signaling targets in the brain, including cells of the anterior pituitary (AP). We have previously reported that mice lack
Publikováno v:
Cancer Research. 81:1892-1892
Since 2014, immune checkpoint inhibitors (ICIs) have led the charge against metastatic melanoma as the most commonly utilized first-line treatment. While ICIs have dramatically increased the 5-year overall survival rate, only half of patients respond